Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes drug formulation and use claims relating to Diffusion's entire family of first-in-class new chemical entities. Diffusion Pharmaceuticals is commercializing this family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level.
“Bipolar Trans Carotenoid Salts and Their Uses.”
"The issuance of this new patent extends protection beyond our lead drug candidate trans sodium crocetinate (TSC) and is an important addition to our current intellectual property portfolio," said David G. Kalergis, Diffusion's CEO.
Currently the Company has nine issued patents and more than 85 pending patent applications filed in all major international markets.
Lancet Commission predicts sharp increase in global prostate cancer cases